Key Personnel Additions Cyteir Therapeutics has made strategic hires in key positions like Chief Financial Officer, General Counsel, and board directors, indicating a focus on strengthening corporate leadership. These additions could present opportunities for partnership discussions and business collaborations.
Recent Funding With a recent funding round of $80M, Cyteir Therapeutics has the financial resources to support its research and development efforts. This financial stability could open up opportunities for potential investors, suppliers, or clients looking to engage with a well-funded company in the oncology space.
Market Performance Despite a recent IPO, Cyteir Therapeutics has experienced a decline in its stock price. Monitoring market trends and engaging with the company during this phase could provide an opportunity to assess potential partnerships or investments at a favorable valuation.
Sustainable Oncology Focus Cyteir Therapeutics is focused on developing next-generation therapies for cancer treatment, emphasizing a sustainable approach to oncology. Businesses aligned with sustainable healthcare practices may find common ground with Cyteir for potential collaborations or joint initiatives.
Tech Stack Analysis By leveraging technologies like Cloudflare, Google Font API, and PHP, Cyteir Therapeutics demonstrates a commitment to utilizing cutting-edge tools in its operations. Technology providers or vendors offering complementary solutions could explore partnership opportunities with Cyteir to enhance efficiencies.
90
$10M$50M
2$10M
11$10M
176$10M$50M
51$10M$50M
107$10M$50M
501$50M$100M
86$10M$50M
731$100M$1B
281$10M$50M
65$10M$50M
46$10MCyteir Therapeutics uses 8 technology products and services including Cloudflare, Google Font API, Swiper, and more. Explore Cyteir Therapeutics's tech stack below.
| Cyteir Therapeutics Email Formats | Percentage |
| First.Last@cyteir.com | 46% |
| FirstLast@cyteir.com | 4% |
| First.Last@cyteir.com | 46% |
| FirstLast@cyteir.com | 4% |
Research ServicesMassachusetts, United States11-50 Employees
Cyteir was a clinical-stage oncology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir had CYT-0851 in development in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
Company Overview
Media & News
Funding & FinancialsCyteir Therapeutics has raised a total of $80M of funding over 5 rounds. Their latest funding round was raised on Feb 11, 2021 in the amount of $80M.
Funding & FinancialsCyteir Therapeutics has raised a total of $80M of funding over 5 rounds. Their latest funding round was raised on Feb 11, 2021 in the amount of $80M.
1-888-653-2347 
support@leadiq.com